• TG Therapeutics EPS for the quarter ending December 31, 2024 was $0.16, a 900% decline year-over-year.
• TG Therapeutics 2024 annual EPS was $0.15, a 66.67% increase from 2023.
• TG Therapeutics 2023 annual EPS was $0.09, a 105.45% decline from 2022.
• TG Therapeutics 2022 annual EPS was $-1.65, a 37.26% decline from 2021.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.